CTLA4 and neoplasm: Group 2 patients(CTLA-4high tumor cells, densityhigh CTLA-4+ lymphocytes) might benefit most from CTLA-4 blockade treatment, because a sufficient number of preexisting inactive T cells in tumor microenvironment could be re-activated after neutralizing soluble CTLA-4 with CTLA-4 antibodies; ADCC against CTLA-4+ tumor cells might also be induced by CTLA-4 antibodies.